Oncotarget

Research Papers:

Effect of pravastatin on the survival of patients with advanced gastric cancer

Luis Bujanda _, Araceli Rodríguez-González, Cristina Sarasqueta, Emma Eizaguirre, Elizabeth Hijona, José J.G. Marín, María J. Perugorria, Jesús M. Banales and Angel Cosme

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:4379-4384. https://doi.org/10.18632/oncotarget.6777

Metrics: PDF 891 views  |   HTML 1163 views  |   ?  


Abstract

Luis Bujanda1,5, Araceli Rodríguez-González2, Cristina Sarasqueta3, Emma Eizaguirre2, Elizabeth Hijona1,5, José J.G. Marín4,5, María J. Perugorria1,5, Jesús M. Banales 1,5, Angel Cosme1

1Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain

2Department of Surgery, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), San Sebastián, Spain

3Donostia University Hospital, Biodonostia Health Research Institute, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), San Sebastián, Spain

4Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain

5National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain

Correspondence to:

Luis Bujanda, E-mail: medik@telefonica.net

Keywords: gastric cancer, pravastatin, overall survival, advanced

Received: August 19, 2015     Accepted: December 1, 2015     Published: December 28, 2015

ABSTRACT

Objectives: A fluoropyrimidine plus cisplatin combined with surgery is standard first-line treatment for advanced gastric cancer. We evaluated the effect of pravastatin on overall survival in patients with advanced gastric cancer in a prospective cohort study.

Methods: At the time of surgery, we assigned 60 patients with advanced gastric cancer (stage III or IV) to receive standard first-line treatment (control group) or standard first-line treatment plus pravastatin at a dose of 40 mg once daily (pravastatin group). The minimum follow-up period was 4 years and the maximum of 6 years.

Results: The mean of age was 66 years and the TNM stage was III and IV in 65% and 35% of patients, respectively. There was no significant difference between the two groups (control vs pravastatin) in median overall survival (15 vs 14 months; P = 0.8). Predictors of survival were the stage (hazard ratio of death stage IV (III stage as reference): 4.4; 95% CI: 2–9.7; p < 0.05) and older age (hazard ratio of death ≥ 65 years (< 65 years as reference): 2.8; 95% CI: 1.3–6; p < 0.05).

Conclusions: Pravastatin did not improve outcome in patients with advanced gastric cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6777